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CLASSIFICATION SYSTEM OF CHRONIC GVHD IMPACTS RISK FACTORS
Jacobs, R.W., Chen, H., Savani, B.N., Kassim, A., Clifton, C.,
Vaughan, L.A., Lucid, C.E., Jagasia, M. Vanderbilt University Medical
Center, Nashville, TN
Risk factors associated with chronic graft-versus-host-disease
(cGVHD) after allogeneic hematopoietic cell transplantation have
been studied using the limited/extensive (L/E) classification. In
2005, the NIH criteria were proposed and have been validated as
a prognostic tool in retrospective studies. It is unclear if the previ-
ously identified risk factors of cGVHD apply to cGVHD as defined
by NIH criteria. At our center, patients undergoing allo-HCT with
a survival of . 100 days are transitioned to the Long Term Trans-
plant Clinic. Grading and staging of GVHD using NIH criteria (in-
cluding severity) and L/E classification has been done prospectively
since 2006. We analyzed risk factors associated with GVHD after
day 100 and compared the factors using both classifications. Patients
characteristics are summarized in Table 1(n 5 205, cord transplant
excluded). All 11 risk factors were analyzed using univariate analysis.
Table 1. Patient characteristics
Risk Factor Variable N (205) %1 Age, median, (range) years 47 (18-70)
2 Regiment Intensity:Ablative/other 110/94 54/46
TBI*: yes/no 75/129 37/633 Gender:
Female donor-> male recipient/other 54/140 28/724 Donor Type:
Related/Unrelated 120/84V 59/41V5 Stem Cell Source:
Peripheral Blood/Bone Marrow 166/39 81/196 Disease Risk Status (CIBMTR)
Low 105 51
Intermediate 61 30
High 26 137 CMV #:
R/DU +/+ vs. other 68/130 34/668 Acute GVHD-maximum grade:
0-1 vs. 2-4 53/143 27/739 Day 100 - on steroids:
Yes/No 87/110 44/5610 Platelet count (x 10^9/L):
< 100 vs. $ 100 80/116 41/5911 Day 100 total bilirubin (mg/dL):
Median (range) .8 (.2-2.6)
Limited/extensive GVHD
Classification
None 44 21
Limited 33 16
Extensive 128 62
NIH Criteria - GVHD Classification
None 44 21
Acute subtypes 33 16
Classic/Overlap cGVHD 128 62
Severityv
Mild 6 5
Moderate 55 43
Severe 65 51*Total body irradiation, # CMV-cytomegalovirus, U R/D-recipient/
donor, v applicable for classic/overlap cGVHD only, V 37/84 unrelated
donors received in-vivo T-cell depletion.
GVHDbeyond day 100was seen in 151 of 205 patients (76%). Bonemar-
row (BM) (versus PBSC) as graft source (61% vs. 82%, P\0.001), and use
of in vivo T-cell depletion (versus no T-cell depletion) (54% vs. 84%, P\
0.0001) was associated with decreased L/E cGVHD. Using the NIH clas-
sification, BM (38% vs. 70%, P5 0.003) and in vivo T cell depletion (32%
vs. 73%, P\ 0.001) had a lower incidence of classic/overlap cGVHD
compared to no GVHD. Grade 2-4 acute GVHD (aGVHD) and use of
steroids for aGVHD at day 100 was associated with a higher incidence
of acute subtypes/noGVHDbeyondday 100 compared to classic/overlap
cGVHD (69% vs. 31%, P5 0.018; 67% vs. 33%, P5 0.052). Adjusted fordonor type, aGVHD, andday 100 steroid use, only BMas stemcell source
was an independent predictor of decreased L/E cGVHD (OR 0.37, P 5
0.017). BM as stem cell source, remained an independent factor for
decreased classic/overlap cGVHD (OR 0.3, P5 0.009). The 2 yr overall
survival (OS) for the entire cohort was 86% (95% CI, 81.6- 92). Patients
with classic/overlap cGVHD had a superior OS compared to acute
subtypes/none (P 5 0.005). Only stem cell source (BM) remained an
independent predictor of OS (HR 2.38, 95% CI 1.05-5.41, P 5 0.039).
This study shows that graft source remains an important risk
factor of cGVHD irrespective of the classification system, but the
incidence of cGVHD using the NIH criteria is significantly lower.
Other known risk factors of L/E cGVHD were not predictive of
cGVHD as defined by the NIH criteria.487
MAST CELLS SUPPRESS GVHD IN A MECHANISM INDEPENDENT OF
CD4+CD25+ REGULATORY T CELLS
Leveson-Gower, D.B.1, Sega, E.I.1, Kalesnikoff, J.2, Florek, M.1,
Galli, S.J.2, Negrin, R.S.1 1StanfordUniversity, Stanford, CA; 2Stanford
University, Stanford, CA
Mast cells, which are importantmediators of both innate and adap-
tive immune responses, have been shown to have anti-inflammatory
roles in some experimental models. Previous studies have hypothe-
sized that CD4+CD25+ regulatory T cells (Tregs) may ‘‘recruit’’
mast cells as part of a mechanism of inducing tolerance to allografts,
and also that mast cells may be able to induce CD4+ T cells into
CD4+CD25+Foxp3+ cells. In this study,we exploredwhether the sup-
pressionof graft-versus-host disease (GVHD)byTregs involvesmast
cells in a major MHC-mismatch model of GVHD. C57BL/6 (H-2b)
recipient mice were treated with myeloablative irradiation and 5x106
T-cell depleted bone marrow cells (TCD-BM) from FVB/N donors
(H-2q), followed by transfer of 2x106 FVB/NCD4 andCD8 conven-
tional T cells (Tcon) to induceGVHD.To suppress GVHD, groups
were given Treg at a Treg:Tcon ratio of 1:3. Equivalent suppression
of GVHD was observed with Treg in both wild-type C57BL/6 or
C57BL/6-KitW-sh/W-sh recipient mice (which virtually lack mast
cells), indicating that Treg suppression of GVHD in this model did
not involvemast cells. Furthermore, the percentage of Foxp3 positive
Treg cellswas similar before and after transplantation inKitW-sh/W-sh
andWT recipients, and CD4+CD25hi Treg from KitW-sh/W-sh mice
were equally capable of suppressing T cell proliferation in a mixed
leukocyte reaction. However, survival of recipients receiving TCD-
BM and Tcon only was significantly reduced in animals lacking
mast cells, where 100% of KitW-sh/W-sh recipients died by day 15 of
transplantation, yet over 50% of WT recipients were alive at day
60 (p\0.0001). While IL-10 was present at low-levels in the serum
of wild-type recipients of Tcon (mean50 pg/mL), IL-10 was
undetectable in the serum of KitW-sh/W-sh recipients. Furthermore,
preliminary experiments have indicated that KitW-sh/W-sh that have
had their gut and other sites engrafted by transfer of 5x106 bone
marrow-derived cultured mast cells (BMCMCs) i.p., have improved
survival over untreated KitW-sh/W-sh, but not if BMCMCs were de-
rived from IL-10-/- mice. Finally we observe that KitW-sh/W-sh have
greatly increased amounts ofTcon proliferation in lymph node, liver,
and gastrointestinal tract tissue sites, as indicated by bioluminescence
imaging (BLI) (p\ 0.001). Thus, we propose that the presence of
mast cells significantly reduces GVHD, independent of Treg, by
releasing IL-10 and decreasing Tcon proliferation.488
CYCLOSPORINE AND METHOTREXATE (CSA/MTX) COMPARED WITH CY-
CLOSPORINE AND MYCOPHENOLATE MOFETIL (CSA/MMF) AS GVHD
PREVENTION REGIMENS IN ALLOGENEIC STEM-CELL TRANSPLANTA-
TION FROM UNRELATED DONORS; RELATIVE OUTCOMES ARE DEPEN-
DANT ON DISEASE STATUS AT TRANSPLANTATION
Shimoni,A., Shem-Tov,N., Rand,A., Roth, S.,Volchek, Y., Yerushalmi,R.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic stem cell transplantation (SCT) from matched unre-
lated donors (MUD) is a potentially curative approach in patients
(pts) with hematologic malignancies and no sibling donor. Several
GVHD prevention regimens have been used but there is no data
Poster Session II S329to support one over the others.We historically usedCSA/MTX (n5
187pts).Over the last 3 yearswe usedCSA/MMF(n592).Medianpt
age was 52 years (18-73). Diagnoses included AML/MDS (n5 152),
ALL (n5 30),CML (n5 12),myeloma (n5 24), lymphoma (n5 40),
others (n5 21).The donorwas 10/10 (n5 191), 9/10 (n554) or# 8/
10 match (n 5 34). Conditioning was myeloablative (n 5 58) or
reduced intensity/toxicity (RIC, n 5 221). Non-relapse mortality
(NRM) is dependant on regimen toxicity and GVHD. CSA/MMF
was less toxic than CSA/MTX. It allowed faster engraftment, day
+11 and +14, respectively (p\ 0.001). Day30 mortality was 2.2%
and 10.7%, respectively (p 5 0.04). Multivariate analysis (MVA)
identified high comorbidity index (HR 2.5, p 5 0.05), advanced
disease (HR 6.2, p 5 0.005), mismatched donor (HR 2.4, p 5 0.03)
and lymphoid malignancies (HR 2.8, p 5 0.03) as adverse factors
for regimen-related mortality. CSA/MMF was protective (HR 0.4,
p50.02).However,CSA/MMFwas less effective inpreventinggrade
III-IV acute GVHD; cumulative incidence 29% and 18%, respec-
tively (p 5 0.005). MVA identified mismatched donor (HR 3.4, p 5
0.001) and CSA/MMF (HR 2.4, p5 0.004) as adverse factors, while
RICwas protective (HR 0.4, p5 0.01). The net effect was that NRM
was equivalent with both regimens. GVHD regimen had major im-
pact on overall survival (OS) when pts were stratified based on disease
status. In early stage disease, OSwas 65% and 42%, after CSA/MTX
and CSA/MMF, respectively (HR 1.9, p5 0.05), predominantly due
to excess GVHDdeaths in theMMF group. In advanced disease, OS
was betterwithCSA/MMF; 20%and 12%, respectively (HR0.5, p5
0.04), predominantly due to less relapses. In conclusion, GVHDpre-
vention regimen has major impact on outcome after MUD SCT.
CSA/MMF is a less toxic regimen and allows prompt engraftment,
but is less effective in preventing GVHD. In early stage disease, out-
come is dominated by NRM and more effective GVHD prevention
regimen such as CSA/MTX is needed. In advanced disease both tox-
icity and relapse increase. A less intensive regimen, that also better
preserves GVL, such as CSA/MMF, may be associated with better
outcome. The GVHD prevention regimen selected may need to be
tailored to pt and disease characteristics.489
RITUXIMAB TREATMENT IN CHRONIC GVHD: CLINICAL EFFICACY ASSO-
CIATES WITH RESTORING A PHYSIOLOGICAL B-CELL BALANCE
van Dorp, S.1, Resemann, H.K.2, te Boome, L.C.J.2, Lokhosrt, H.M.2,
Petersen, E.J.2, Minnema, M.C.2, Ebeling, S.B.1, de Weger, R.A.3, van
Dijk, M.R.3, Meijer, E.2, Kuball, J.H.E.1,2 1UMCU, Utrecht, Utrecht,
Netherlands; 2UMCU, Utrecht, Utrecht, Netherlands; 3UMCU,
Utrecht, Utrecht, Netherlands
Introduction:Chronic graft-versus-host disease (cGVHD) is thema-
jor long termcomplicationof allogeneic stemcell transplantation (allo-
SCT). Although the contribution of donor T cells in the development
ofGVHDisbeyonddoubt, the role of B cells is less defined.Promising
results of B-cell depleting therapy with rituximab (RTX), suggest that
B cells do contribute to cGVHD. However, there is no consensus on
the exact mechanism by which B cells can cause allo-reactivity.
Objective: In order to elucidate efficacy in a prospective clinical trial
and elucidate the potential role of B cells in allo-reactivity and how
B-cell depletion results in amelioration of steroid refractory exten-
sive cGVHD, T- and B-cell subsets were studied before and after
RTX treatment.
Methods: In a prospectivephase I/II study 20patientswith steroid-re-
fractory extensive cGVHD were treated with RTX (4 x 375 mg/m2).
Clinical responses were monitored monthly for 1 year according to
the NIH criteria. T-cell and B-cell subsets and phenotypes were ana-
lyzed before and after treatment in responders andnon-responders and
compared to time matched no GVHD controls (no GVHD) and
healthy donors (HD) by FACS analysis. (EudraCT 2008-004125-42).
Results: A total of 80 RTX infusions were administered to 20 pa-
tients. Toxicity was limited to one infectious event and one allergic
reaction. Median follow-up was 6.5 months (range 1-13). Overall
response rate was 62%. Best clinical responses were observed in
patients with deep sclerosis of the skin (80%). Before treatment
absolute numbers of B cells were increased in responders compared
to non-responders, no GVHD and HD. Moreover, selectively in re-
sponders also the balance within B-cell subsets was disturbed. One
year after RTX treatment B-cells could be detected and responders
had a restored physiological B-cell phenotype.Conclusion: RTX treatment is a feasible and effective treatment in
patients with steroid refractory cGVHD. Sclerotic lesions of the skin
are most susceptible to treatment. In responders the increase in B
cells before treatment and the disturbed phenotype suggest that a dis-
balance in B cells is involved in inducing cGVHD. This allows to
speculate that cGVHD is heterogenous and can be either B-cell or
rather T-cell mediated. Analyzing B-cell numbers and phenotype
in patients with cGVHD might be useful in upfront identification
of patients which will benefit from RTX treatment and include
patients which will not in alternative clinical trials.490
STANDARDIZED EARLY INITIATION OF A ‘‘HIGH DOSE STEROID (HDS)’’
TREATMENT PROTOCOL FOR ALLO-IMMUNE LUNG SYNDROMES IS
ASSOCIATED WITH IMPROVED SURVIVAL DESPITE THE PRESENCE OF
HIGH VIRAL LOADS OF ‘‘COMMON COLD VIRUSES’’
Boelens, J.J.1, Versluys, B.1, Lindemans, C.1, Terhegge-Lagro, S.2,
Bierings, M.1 1UMC Utrecht, Utrecht, Netherlands; 2UMC Utrecht,
Utrecht, Netherlands
Background: Alloimmune lung syndromes (allo-LS), including Id-
iopathic Pneumonia Syndrome (IPS) and Bronchiolitis Obliterans
(BOS), are severe life-treatening complications after HSCT.We re-
cently found that a ‘‘common cold’’ respiratory viral (RV) infection
early after HSCT is an important predictor for the development of
allo-LS and that prolonged administration of immunosuppression,
in patients with a RV infection, because of aGVHD, paradoxically
had a protective effect on the development of allo-LS (BBMT
2010). We therefore hypothesised that despite presence of a RV,
alloLD should be treated with ‘high dose steroids (HDS)’’. We pro-
spectively studied the outcomes of the treatment of allo-immune
lungsyndromes (alloLS) with a standard HDS-protocol’’ and com-
pared this with our historical cohort.
Methods: All patients transplanted between January 2004 and July
2010, within our pediatric transplant program were included. All pa-
tients were tested for the presence of a RV using qPCR prior to
HSCT and subsequently weekly till discharge. After discharge
only when having symptoms. Allo-LS (IPS or BOS) was diagnosed
according international criteria, excluding infection (except presence
of a RV). In 2006 the HDS treatment protocol was introduced when
allo-LS was suspected: MP-pulse (10mg/kg: 3 days), followed by
2mg/kg/d prednisone, tapered 25% per week till 0.5mg/kg. After 4
weeks the MP-pulse was repeated, followed by 0.5mg/kg/d for at
least 1 months. In case there was still suspicion of disease the MP-
pulse was repeated (max. 6times). Ciclosporine tough levels were
maintained between 150 and 250 ug/L. In the old treatment guide-
lines we were reluctant giving HDS because of the presence of a RV.
Results: 182 patients were included of whom 38 (21%; 15% IPS and
6%BO) developed an allo-LS. 35/38 of the patients with an alloLS
had a proven RV. Follow up: 36mths (1–76 mths). The overall
survival was 63% (73% without alloLS, 43% with alloLS). Cause
of death in the alloLS group was 90% TRM and 10% relapse. 10
pts were treated according to old treatment guidelines, while 28
were included in the HDS protocol. The probability of OS was
20% for the ‘‘old treatment group’’ while 54% of the patients within
the HDS group survived (p 5 0.041). The viral load of the RV,
expressed as CT-values, remained stable (median value 20: range
17 – 24) during the treatment with HDS.
In summary: Early initiation of HDS in alloLS improved survival,
despite the presence of a RV (infection).491
DISTINCT OLIGOCLONAL T CELLS ARE ASSOCIATED WITH GVHD OR
GVHD-FREE RESPONSES IN PATIENTS WITH HEMATOLOGIC MALIGNAN-
CIES FOLLOWING STEM CELL TRANSPLANTATION
Toor, A.A.1, Kmieciak,M.2, Berrie, J.L.2, Mallory, K.L.2, Roberts, C.H.1,
Sabo, R.1, Idowu, M.1, Chung, H.M.1, Veronica, B.1, Clark, W.B.1,
McCarty, J.M.1, Detwiler, M.3, Kazim, L.3, Manjili, M.H.2 1Virginia
Commonwealth University, Richmond, VA; 2Virginia Commonwealth
University, Richmond, VA; 3Roswell Park Cancer Institute, Buffalo, NY
Graft-versus-host disease (GVHD) and graft-versus-tumor
(GVT) effects observed following allogeneic stem cell transplanta-
tion may be associated with unique clonal T cell expansion. To
